For most of the last decade, the way a companion animal medicine was administered was a clinical question. Oral or injectable, daily or monthly, was something you settled with the veterinary team and then handed to marketing as a fact of the product.
That is no longer what it is. Route of administration has quietly become the strongest predictor of whether a brand keeps its margin once the prescription leaves the building. It is a channel decision now, and most portfolios were built before anyone treated it as one.
The link that broke
A prescription written in a clinic used to be filled in that clinic. The dispensing margin and the compliance conversation stayed in the same room as the diagnosis.
Online pharmacy broke that link for anything a pet owner can swallow, chew or apply at home. The script still originates with the veterinarian, but the fulfilment, the autoship discount, the reorder reminder and the relationship with the household all move somewhere else. The clinic keeps the clinical responsibility and loses the transaction.
Retail is pushing from the other side, connecting mobile veterinary services directly to pharmacy fulfilment and its own store footprint. That is not a pharmacy competing with a clinic. That is a retailer assembling the whole pathway.
Here is the part worth sitting with. None of it reaches an injectable biologic administered in the clinic.
The moat, stated plainly
Some products can be fulfilled anywhere. Some cannot leave the building.
A monoclonal antibody given by injection during a visit is not a package. It is an appointment. It requires the animal to be present, a professional to administer it, and a return visit on an interval the clinician sets. No online pharmacy can intercept that, because there is nothing to ship to a household.
That is the dispensing moat. It is not built on efficacy, price or brand preference. It is built on the physical requirement that the patient be in the room.
What the numbers already say
Canine dermatology is where you can watch this happen, because the category now contains both types at once.
The oral side is crowded and exposed. Three oral JAK inhibitors compete for the same scripts, and every one is a tablet an owner can have filled online. Elanco reported Zenrelia in roughly 18,000 US clinics, over 60% of the clinic base, with more than 2.5 million dogs treated. Credelio Quattro passed 50% of the US clinic base, up around 3,000 clinics in a single quarter.
Meanwhile Zoetis reported dermatology revenue of $395 million globally in the second quarter, down 16%, with US in clinic share still around 86% but down roughly 10 points year over year.
Read those together carefully, because the obvious conclusion is the wrong one. The incumbent is not losing because its molecules stopped working. It is losing share fastest in the format that is easiest for a competitor to reach and for a pharmacy to fulfil.
Now look at what both companies are building next. Elanco launched an injectable anti-IL-31 antibody in May. Zoetis is advancing a long acting version of its own injectable toward a three month interval. Two competitors, same category, both investing in the format that cannot be shipped to a house. That is not coincidence. That is two companies reading the same map.
Why the interval matters more than it looks
A quarterly injectable is usually sold on convenience. Fewer visits, better adherence, less burden on the owner.
The commercial argument is larger. Every dose is an appointment the clinic owns. A three month interval turns a chronic condition into four guaranteed clinic touchpoints a year, each one a diagnosis opportunity, a weight check, a chance to discuss something else entirely.
Compare that with a daily tablet on autoship, where the clinic may not see the animal again for a year and has no visibility into whether the course was completed.
The interval is not the product feature. The visit is the product feature.
What to do with your portfolio
Sort your products into two lists. Not by therapeutic area, not by brand tier. By whether the medicine can be fulfilled without the animal being present.
Products that can leave the building are orals, topicals, anything an owner administers. These compete on price, availability and autoship convenience, against a pharmacy with better logistics than you have. Defend them with formulation, dosing schedules and clinic economics, and accept that the transaction is contestable.
Products that cannot leave the building are injectables, in clinic diagnostics, anything requiring professional administration. These compete on clinical outcome and practice workflow, and the channel cannot be disintermediated. Your margin here is structurally safer.
Most portfolios lean heavily to the first list, because that is where volume has always been. The question your next plan has to answer is whether your pipeline is rebalancing toward the second.
The uncomfortable part
This is not an argument that injectables are better medicine. They are not inherently better. An oral is right for many patients and many households, and a veterinarian choosing a tablet is making a clinical decision that deserves respect, not a channel decision.
It is an argument that the commercial characteristics of the two formats have diverged sharply, and that most brand plans still treat route of administration as a clinical footnote rather than the channel decision it has become.
For each of your top five products, ask one question. If the prescription is filled somewhere other than the clinic that wrote it, what did we lose? For some the honest answer is very little. For others it is the reorder, the compliance data, the next visit and the relationship.
If you want the named specifics behind the figures above, they are on the live dashboard at VetLaunchLab.com, sourced to each company's own results release. The weekly brief carries the channel moves as they happen, and we are happy to walk a commercial team through the category view.